Susanna Naggie, MD

Professor of Medicine
Vice Dean for Clinical Research
Member in the Duke Clinical Research Institute
Campus mail 300 West Morgan St, Suite 800, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Lok, Anna S., Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, and William G. Powderly. “Benefits of Direct-Acting Antivirals for Hepatitis C.” Ann Intern Med 167, no. 11 (December 5, 2017): 812–13. https://doi.org/10.7326/M17-1876.

PMID
29049502
Full Text

Zuckerman, Autumn, Cody A. Chastain, and Susanna Naggie. “Retreatment Options Following HCV Direct Acting Antiviral Failure.” Curr Treat Options Infect Dis 9, no. 4 (December 2017): 389–402. https://doi.org/10.1007/s40506-017-0136-6.

PMID
29242710
Full Text

Powderly, William G., Susanna Naggie, Arthur Y. Kim, Hugo E. Vargas, Raymond T. Chung, and Anna S. Lok. “IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.” Clin Infect Dis 65, no. 11 (November 13, 2017): 1773–75. https://doi.org/10.1093/cid/cix620.

PMID
29020156
Full Text

Babich, Tanya, Oren Zusman, Michal Elbaz, Haim Ben-Zvi, Mical Paul, Leonard Leibovici, and Tomer Avni. “Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study.” Clinical Infectious Diseases 65, no. 11 (November 13, 2017): 1799–1805. https://doi.org/10.1093/cid/cix680.

Full Text

Naggie, Susanna, Daniel S. Fierer, Michael Hughes, Arthur Y. Kim, Anne Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. “100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals).” In Hepatology, 66:113A-113A. WILEY, 2017.

Scholars@Duke

Lok, Anna S., Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, and William G. Powderly. “Comments on cochrane review on direct-acting antivirals for hepatitis C.” Hepatology 66, no. 4 (October 2017): 1016–19. https://doi.org/10.1002/hep.29366.

PMID
28714142
Full Text

Wyles, David, Norbert Bräu, Shyam Kottilil, Eric S. Daar, Peter Ruane, Kimberly Workowski, Anne Luetkemeyer, et al. “Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.” Clin Infect Dis 65, no. 1 (July 1, 2017): 6–12. https://doi.org/10.1093/cid/cix260.

PMID
28369210
Full Text

Burton, Mary Jane, and Susanna Naggie. “Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.” Clin Infect Dis 64, no. 12 (June 15, 2017): 1721–23. https://doi.org/10.1093/cid/cix117.

PMID
28199517
Full Text

Naggie, Susanna, Kristen M. Marks, Michael Hughes, Daniel S. Fierer, Christine Macbrayne, Arthur Kim, Kimberly Hollabaugh, et al. “Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.” In Clin Infect Dis, 64:1035–42, 2017. https://doi.org/10.1093/cid/cix025.

PMID
28329053
Full Text

Pages